## Theodore R Levin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2798082/publications.pdf

Version: 2024-02-01

23472 28190 21,920 113 55 111 citations h-index g-index papers 118 118 118 15519 docs citations times ranked citing authors all docs

| #  | Article   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing. Clinical Gastroenterology and Hepatology, 2022, 20, 145-152.  | 2.4   | 21        |
| 2  | Risk stratification for colorectal cancer in individuals with subtypes of serrated polyps. Gut, 2022, 71, 2022-2029.  | 6.1   | 14        |
| 3  | Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study Journal of Clinical Oncology, 2022, 40, TPS208-TPS208.  | 0.8   | 5         |
| 4  | Association between Improved Colorectal Screening and Racial Disparities. New England Journal of Medicine, 2022, 386, 796-798.  | 13.9  | 28        |
| 5  | Current and future colorectal cancer screening strategies. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 521-531.   | 8.2   | 102       |
| 6  | Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population. Gastroenterology, 2022, 163, 723-731.e6.                     | 0.6   | 18        |
| 7  | Disparities in Preventable Mortality from Colorectal Cancer: Are They the Result of Structural Racism?. Gastroenterology, 2021, 160, 1022-1025.   | 0.6   | 9         |
| 8  | Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details. Clinical Gastroenterology and Hepatology, 2021, 19, 1793-1795.   | 2.4   | 0         |
| 9  | Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large,<br>Community-based Population. Gastroenterology, 2020, 158, 884-894.e5.   | 0.6   | 85        |
| 10 | Early Screening of African Americans (45–50 Years Old) in a Fecal Immunochemical Test–Based Colorectal Cancer Screening Program. Gastroenterology, 2020, 159, 1695-1704.e1.   | 0.6   | 18        |
| 11 | Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory<br>Test and Demographic Data in Diverse, Community-Based Population. Clinical Gastroenterology and<br>Hepatology, 2020, 18, 2734-2741.e6. | 2.4   | 14        |
| 12 | What Is Organized Screening and What Is Its Value?. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 393-411.   | 0.6   | 15        |
| 13 | Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit. Ca-A Cancer Journal for Clinicians, 2020, 70, 283-298.                                 | 157.7 | 75        |
| 14 | Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps.<br>Gastroenterology, 2020, 159, 502-511.e2.   | 0.6   | 27        |
| 15 | Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal<br>Immunochemical Test. Population Health Management, 2019, 22, 83-89.  | 0.8   | 4         |
| 16 | Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Annals of Internal Medicine, 2019, 170, 736.  | 2.0   | 2         |
| 17 | Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. Clinical and Translational Gastroenterology, 2019, 10, e00010.   | 1.3   | 27        |
| 18 | Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings. JAMA Internal Medicine, 2019, 179, 153.  | 2.6   | 57        |

| #  | Article  | IF  | Citations |
|----|--|-----|-----------|
| 19 | Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology, 2019, 156, 63-74.e6.  | 0.6 | 78        |
| 20 | Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. Journal of Clinical Gastroenterology, 2019, 53, e25-e30.  | 1.1 | 24        |
| 21 | Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut, 2018, 67, 291-298.  | 6.1 | 264       |
| 22 | Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcareÂsetting. Gastrointestinal Endoscopy, 2018, 87, 755-765.e1.                    | 0.5 | 28        |
| 23 | Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening. Clinical and Translational Gastroenterology, 2018, 9, e186. | 1.3 | 6         |
| 24 | In Screening for Colorectal Cancer, Is the FIT Right for the Right Side of the Colon?. Annals of Internal Medicine, 2018, 169, 650.  | 2.0 | 7         |
| 25 | Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology, 2018, 155, 1383-1391.e5.   | 0.6 | 329       |
| 26 | Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Annals of Internal Medicine, 2018, 169, 439-447.   | 2.0 | 47        |
| 27 | Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. BMC Cancer, 2018, 18, 509.  | 1.1 | 15        |
| 28 | Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. American Journal of Preventive Medicine, 2017, 53, 335-344.   | 1.6 | 13        |
| 29 | Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA - Journal of the American Medical Association, 2017, 317, 1631.     | 3.8 | 198       |
| 30 | Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 153, 307-323.                                      | 0.6 | 512       |
| 31 | Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S.<br>Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112,<br>1016-1030.          | 0.2 | 483       |
| 32 | In simulation modelling, there are multiple ways to effectively screen for colorectal cancer. Evidence-Based Medicine, 2017, 22, 59-59.  | 0.6 | 0         |
| 33 | Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Digestive Diseases and Sciences, 2017, 62, 678-688.   | 1.1 | 12        |
| 34 | Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests. Annals of Internal Medicine, 2017, 167, 565.  | 2.0 | 91        |
| 35 | A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. American Journal of Gastroenterology, 2017, 112, 1728-1735.  | 0.2 | 56        |
| 36 | Colorectal Cancer Screening: Money Isn't Everything ButÂltÂHelps!. Gastroenterology, 2017, 153, 1181-1183.   | 0.6 | 4         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The Best Laid Plans: Adaptation is an Essential Part of Going From Efficacy Research to Program Implementation. Gastroenterology, 2017, 152, 693-694.  | 0.6 | 1         |
| 38 | Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2017, 86, 18-33.   | 0.5 | 145       |
| 39 | Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 37-53. | 0.2 | 56        |
| 40 | Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 152, 1217-1237.e3.              | 0.6 | 268       |
| 41 | Recommendations on fecal immunochemical testing to screen forÂcolorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointestinal Endoscopy, 2017, 85, 2-21.e3.          | 0.5 | 55        |
| 42 | Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 85-94.   | 1.1 | 168       |
| 43 | Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. Journal of General Internal Medicine, 2016, 31, 1323-1330.                   | 1.3 | 50        |
| 44 | Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. Journal of the American Board of Family Medicine, 2016, 29, 672-681.  | 0.8 | 24        |
| 45 | Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening. Annals of Internal Medicine, 2016, 164, 456.  | 2.0 | 186       |
| 46 | Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectalÂcancer. Gastrointestinal Endoscopy, 2016, 83, 489-498.e10.                                    | 0.5 | 20        |
| 47 | Ten-year incidence of colorectal cancer following a negative screening sigmoidoscopy: an update from the Colorectal Cancer Prevention (CoCaP) programme. Gut, 2016, 65, 271-277.   | 6.1 | 3         |
| 48 | Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 344-350.  | 1.1 | 106       |
| 49 | Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US<br>Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2016, 111,<br>337-346.                       | 0.2 | 59        |
| 50 | Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2016, 150, 758-768.e11.   | 0.6 | 151       |
| 51 | Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. Gastrointestinal Endoscopy, 2016, 83, 552-554.   | 0.5 | 9         |
| 52 | Colorectal cancer deaths attributable to nonuse of screening in the United States. Annals of Epidemiology, 2015, 25, 208-213.e1.   | 0.9 | 102       |
| 53 | Development and validation of an algorithm for classifying colonoscopy indication. Gastrointestinal Endoscopy, 2015, 81, 575-582.e4.   | 0.5 | 26        |
| 54 | Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 313, 2349.  | 3.8 | 72        |

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. BMC Cancer, 2015, 15, 123.  | 1.1  | 17        |
| 56 | Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer, 2015, 121, 2281-2285.  | 2.0  | 180       |
| 57 | CDC Grand Rounds: the future of cancer screening. Morbidity and Mortality Weekly Report, 2015, 64, 324-7.  | 9.0  | 5         |
| 58 | Adenoma Detection Rate and Risk of Colorectal Cancer and Death. New England Journal of Medicine, 2014, 370, 1298-1306.   | 13.9 | 1,653     |
| 59 | Multitarget Stool DNA Testing for Colorectal-Cancer Screening. New England Journal of Medicine, 2014, 370, 1287-1297.  | 13.9 | 1,352     |
| 60 | The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1147-1158. | 1.1  | 64        |
| 61 | Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 543-562.  | 0.5  | 106       |
| 62 | Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1528-1545.   | 0.2  | 119       |
| 63 | Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.  | 0.2  | 363       |
| 64 | Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.  | 0.6  | 397       |
| 65 | Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US<br>Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2014, 147, 903-924.  | 0.6  | 322       |
| 66 | Accuracy of Fecal Immunochemical Tests for Colorectal Cancer. Annals of Internal Medicine, 2014, 160, 171-181.   | 2.0  | 528       |
| 67 | The Road Ahead: What if Gastroenterologists Were Accountable for Preventing Colorectal Cancer?. Clinical Gastroenterology and Hepatology, 2013, 11, 204-207.   | 2.4  | 18        |
| 68 | Health Benefits and Cost-effectiveness of a Hybrid Screening Strategy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2013, 11, 1158-1166.  | 2.4  | 40        |
| 69 | Variation of Adenoma Prevalence by Age, Sex, Race, and Colon Location in a Large Population:<br>Implications for Screening and Quality Programs. Clinical Gastroenterology and Hepatology, 2013, 11,<br>172-180.                                       | 2.4  | 197       |
| 70 | Effectiveness and Reach of the FLU-FIT Program in an Integrated Health Care System: A Multisite Randomized Trial. American Journal of Public Health, 2013, 103, 1128-1133.   | 1.5  | 25        |
| 71 | Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults. Annals of Internal Medicine, 2013, 158, 312.  | 2.0  | 142       |
| 72 | The Importance of Choosing Colorectal Cancer Screening Tests. Archives of Internal Medicine, 2012, 172, 582.   | 4.3  | 6         |

| #  | Article   | IF    | CITATIONS |
|----|---|-------|-----------|
| 73 | Editorial: Taking FIT to the People: Out of the Office and Into the Mail. American Journal of Gastroenterology, 2012, 107, 108-110.   | 0.2   | 4         |
| 74 | Diagnosis, Comorbidities, and Management of Irritable Bowel Syndrome in Patients in a Large Health Maintenance Organization. Clinical Gastroenterology and Hepatology, 2012, 10, 37-45.   | 2.4   | 72        |
| 75 | Incidence and Mortality of Colorectal Adenocarcinoma in Persons With Inflammatory Bowel Disease From 1998 to 2010. Gastroenterology, 2012, 143, 382-389.  | 0.6   | 273       |
| 76 | Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2012, 143, 844-857.  | 0.6   | 1,717     |
| 77 | Automated phone and mail population outreach to promote colorectal cancer screening. American Journal of Managed Care, 2012, 18, 370-8.   | 0.8   | 26        |
| 78 | Optimizing Colorectal Cancer Screening by Getting FIT Right. Gastroenterology, 2011, 141, 1551-1555.  | 0.6   | 17        |
| 79 | Organized Colorectal Cancer Screening in Integrated Health Care Systems. Epidemiologic Reviews, 2011, 33, 101-110.  | 1.3   | 163       |
| 80 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Ca-A Cancer Journal for Clinicians, 2008, 58, 130-160. | 157.7 | 1,491     |
| 81 | Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease. Drug Safety, 2008, 31, 325-334.  | 1.4   | 31        |
| 82 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology, 2008, 134, 1570-1595.                | 0.6   | 2,002     |
| 83 | Dietary Antioxidants, Fruits, and Vegetables and the Risk of Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 1614-1623.   | 0.2   | 80        |
| 84 | Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia. Annals of Internal Medicine, 2008, 149, 441.   | 2.0   | 244       |
| 85 | Implications of New Colorectal Cancer Screening Technologies for Primary Care Practice. Medical Care, 2008, 46, S138-S146.  | 1.1   | 12        |
| 86 | Dealing With Uncertainty: Surveillance Colonoscopy After Polypectomy. American Journal of Gastroenterology, 2007, 102, 1745-1747.   | 0.2   | 9         |
| 87 | Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis, 2007, 28, 1672-1679.  | 1.3   | 93        |
| 88 | Change in Body Size and the Risk of Colorectal Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 526-531.  | 1.1   | 77        |
| 89 | Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics. Journal of the National Cancer Institute, 2007, 99, 1462-1470.   | 3.0   | 346       |
| 90 | Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointestinal Endoscopy, 2007, 65, 757-766.   | 0.5   | 258       |

| #   | Article   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. International Journal of Cancer, 2007, 120, 656-663.  | 2.3 | 177       |
| 92  | Interactions Between CYP2C9 and UGT1A6 Polymorphisms and Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer Prevention. Clinical Gastroenterology and Hepatology, 2006, 4, 894-901.  | 2.4 | 46        |
| 93  | Complications of Colonoscopy in an Integrated Health Care Delivery System. Annals of Internal Medicine, 2006, 145, 880.   | 2.0 | 489       |
| 94  | PPARÎ <sup>3</sup> and Colon and Rectal Cancer: Associations with Specific Tumor Mutations, Aspirin, Ibuprofen and Insulin-Related Genes (United States). Cancer Causes and Control, 2006, 17, 239-249.   | 0.8 | 44        |
| 95  | Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia. Clinical Chemistry, 2006, 52, 2299-2302.   | 1.5 | 20        |
| 96  | Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Research, 2005, 65, 6063-6069.   | 0.4 | 701       |
| 97  | Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut, 2005, 54, 807-813.   | 6.1 | 51        |
| 98  | Associations between apoE genotype and colon and rectal cancer. Carcinogenesis, 2005, 26, 1422-1429.  | 1.3 | 61        |
| 99  | Screening in liver disease: Report of an AASLD clinical workshop. Hepatology, 2004, 39, 1204-1212.  | 3.6 | 57        |
| 100 | Long-Term Drug Treatment of GERD. Disease Management and Health Outcomes, 2004, 12, 399-407.  | 0.3 | 1         |
| 101 | Colorectal cancer screening and surveillance: Clinical guidelines and rationale?Update based on new evidence. Gastroenterology, 2003, 124, 544-560.   | 0.6 | 2,016     |
| 102 | What Does Sigmoidoscopy Really Miss?. American Journal of Gastroenterology, 2003, 98, 2326-2327.  | 0.2 | 2         |
| 103 | Re: Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. Journal of the National Cancer Institute, 2003, 95, 830-831.   | 3.0 | 7         |
| 104 | Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2002, 97, 1296-1308. | 0.2 | 961       |
| 105 | Complications of screening flexible sigmoidoscopy. Gastroenterology, 2002, 123, 1786-1792.  | 0.6 | 103       |
| 106 | Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted?. Gastroenterology Clinics of North America, 2002, 31, 1015-1029.   | 1.0 | 9         |
| 107 | Flexible Sigmoidoscopy. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 23-40.   | 0.6 | 15        |
| 108 | Quality of Life Measurement Clarifies The Cost-Effectiveness of Helicobacter Pylori Eradication in Peptic Ulcer Disease and Uninvestigated Dyspepsia. American Journal of Gastroenterology, 2001, 96, 338-347.  | 0.2 | 48        |

## THEODORE R LEVIN

| #   | Article  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Cimetidine Use and Risk of Breast, Prostate, and Other Cancers. , 2000, 9, 149-155.  |     | 17        |
| 110 | Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization. American Journal of Gastroenterology, 2000, 95, 788-792. | 0.2 | 104       |
| 111 | Predicting Advanced Proximal Colonic Neoplasia With Screening Sigmoidoscopy. JAMA - Journal of the American Medical Association, 1999, 281, 1611.                              | 3.8 | 163       |
| 112 | Omeprazole Improves Peak Expiratory Flow Rate and Quality of Life in Asthmatics With Gastroesophageal Reflux. American Journal of Gastroenterology, 1998, 93, 1060-1063.       | 0.2 | 84        |
| 113 | Costs of Acid-Related Disorders to a Health Maintenance Organization. American Journal of Medicine, 1997, 103, 520-528.  | 0.6 | 102       |